Sigachi Industries reported a consolidated net profit (PAT) of ₹82 million for the first quarter of fiscal 2027 (Q1FY27), marking a 7.89% increase quarter-on-quarter from ₹76 million in Q4FY26. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at ₹165 million, down 31.53% year-on-year from ₹241 million in Q1FY26. Revenue from operations contracted 5.38% YoY to ₹1,213 million, compared to ₹1,282 million in the prior year period.

The improvement in PAT was primarily driven by a significant reduction in finance costs and the absence of exceptional items that weighed on results in the previous year. Finance costs decreased to ₹30 million in Q1FY27 from ₹33 million in Q1FY26 and ₹43 million in Q4FY26. In contrast, Q1FY26 included exceptional items of ₹1,210 million, which resulted in a net loss of ₹1,010 million for that period. Other income also declined to ₹10 million from ₹39 million in Q1FY26.

Financial Performance Breakdown

EBITDA margin narrowed to 13.60% in Q1FY27, down 519 basis points from 18.79% in Q1FY26 but up 97 basis points sequentially from 12.63% in Q4FY26. The profit before tax margin before exceptional items stood at 8.33%, compared to 15.60% in Q1FY26.

Segment Revenue Contribution

The revenue mix shifted slightly during the quarter, with Microcrystalline Cellulose (MCC) contributing 68% of total revenue, down from 80% in Q1FY26. The Active Pharmaceutical Ingredients (API) segment saw its contribution rise to 15% from 7%, while Allied Trades increased to 6% from 3%. Operations and Management contributed 11%, up from 10%.

Conference Call Details

The company has scheduled its earnings conference call to discuss these results on Thursday, August 13, 2026, at 4:30 pm IST. This date follows a postponement announced on July 26, 2026, with the new schedule confirmed via submission to the National Stock Exchange of India Limited and BSE Limited on August 07, 2026.

The teleconference will be hosted by Go India Advisors. Key management participants include Mr. Amit Raj Sinha, Managing Director & CEO; Mr. O. Subbarami Reddy, Chief Financial Officer; and Mr. Vivek Kumar, Company Secretary & Compliance Officer. Investors are required to pre-register using a Diamond Pass to join the session.

Participants should dial in five to ten minutes before the start time. For assistance, attendees may contact Priya Sen, Aadith V, or Riddhi Shah at Go India Advisors.

What the Numbers Show

The divergence between the sharp decline in EBITDA and the swing to net profit highlights a significant improvement in non-operating factors or tax efficiency compared to the prior year. While operational margins compressed by over 500 basis points (from 18.79% to 13.61%), the bottom line moved from a substantial loss of ₹1,010 million to a profit of ₹82 million. This suggests that the prior year’s loss was largely driven by exceptional items of ₹1,210 million, which have normalized in the current quarter. Additionally, the reduction in finance costs from ₹33 million to ₹30 million YoY supported the bottom-line recovery despite the contraction in operating profits.

Sigachi Industries Limited ( sigachi industries ) reported a consolidated net profit of ₹8.14 crore for the quarter ended June 30, 2026, marking a sharp turnaround from the ₹100.97 crore loss recorded in the corresponding period of FY25. The company’s standalone net profit also recovered to ₹6.50 crore, compared to a ₹99.14 crore loss in Q1FY25.

Consolidated revenue from operations stood at ₹121.27 crore, down slightly from ₹128.25 crore in Q1FY25. Standalone revenue was ₹98.28 crore, lower than the ₹110.98 crore reported in the prior year quarter. The previous year’s results were significantly impacted by exceptional losses of ₹121.01 crore, whereas no such exceptional items were reported in the current quarter.

Financial Performance

The company’s profitability improved across both standalone and consolidated metrics. Consolidated profit before tax reached ₹10.09 crore, up from a loss of ₹100.99 crore in Q1FY25. Standalone profit before tax was ₹7.79 crore, compared to a loss of ₹99.20 crore in the same period last year.

Segmental Insights

The pharmaceuticals segment remained the primary revenue driver. Consolidated revenue from pharmaceuticals was ₹108.21 crore, while the operational and management segment contributed ₹13.06 crore. In standalone figures, pharmaceuticals revenue stood at ₹85.22 crore.

Corporate Actions

The Board of Directors, meeting on August 13, 2026, approved the lapse and forfeiture of convertible warrants issued under SEBI ICDR Regulations 2018. A total of 3.51 crore warrants lapsed as holders failed to exercise conversion options within the 18-month tenure. Consequently, an amount of ₹22.87 crore stands forfeited. The warrants were originally allotted on August 10, 2023, at an issue price of ₹26.1 per warrant.

Additionally, the board recommended the re-appointment of Ms. Dhanalakshmi Guntaka and Mr. Janardhana Reddy Yeddula as independent directors for five-year terms, subject to shareholder approval at the ensuing annual general meeting. Mr. Chidambarnathan, retiring by rotation, also offered himself for re-appointment.

What the Numbers Show

The current quarter’s profitability is entirely operational, devoid of the massive exceptional losses that dragged down FY25 results. While revenue declined modestly year-on-year, the absence of exceptional items allowed the company to return to positive net earnings, highlighting a stabilization in core operations despite softer top-line growth.